Design of Cyclic Peptides - Peptide and Protein Design for Biopharmaceutical Applications - page 173

[146] K. D. Kopple et al ., Conformations of Arg-Gly-Asp containing heterodetic cyclic-
peptides - Solution and crystal studies, Journal of the American Chemical Society ,
114, 9615-9623 (1992).
[147] R. M. Scarborough and D. D. Gretler, Platelet glycoprotein IIb-IIIa antagonists as
prototypical integrin blockers: Novel parenteral and potential oral antithrombotic
agents, Journal of Medicinal Chemistry , 43, 3453-3473 (2000).
[148] J. Samanen et al ., Development of a small RGD peptide fibrinogen receptor antago-
nist with potent antiaggregatory activity in vitro, Journal of Medicinal Chemistry ,
34, 3114-3125 (1991).
[149] F. E. Ali et al ., Conformationally constrained peptides and semipeptides derived
from RGD as potent inhibitors of the platelet fibrinogen receptor and platelet-
aggregation, Journal of Medicinal Chemistry , 37, 769-780 (1994).
[150] M. Burger et al ., Small peptide inhibitors of the CXCR4 chemokine receptor
(CD184) antagonize the activation, migration, and antiapoptotic responses of
CXCL12 in chronic lymphocytic leukemia B cells, Blood , 106, 1824-1830
(2005).
[151] C. Murdoch, CXCR4: Chemokine receptor extraordinaire, Immunological

Reviews , 177, 175-184 (2000).
[152] K. Kanbara et al ., Biological and genetic characterization of a human immunode-
ficiency virus strain resistant to CXCR4 antagonist T134, AIDS Research and
Human Retroviruses , 17, 615-622 (2001).
[153] T. Nanki et al ., Stromal cell-derived factor-1-CXC chemokine receptor 4 interac-
tions play a central role in CD4( þ ) T cell accumulation in rheumatoid arthritis
synovium, Journal of Immunology ,165, 6590-6598 (2000).
[154] H. Tamamura et al ., Identification of a CXCR4 antagonist, a T140 analog, as an
anti-rheumatoid arthritis agent, FEBS Letters , 569, 99-104 (2004).
[155] M. Takenaga et al ., A single treatment with microcapsules containing a CXCR4
antagonist suppresses pulmonary metastasis of murine melanoma, Biochemical and
Biophysical Research Communications , 320, 226-232 (2004).
[156] H. Tamamura et al ., T140 analogs as CXCR4 antagonists identified as anti-
metastatic agents in the treatment of breast cancer, FEBS Letters , 550, 79-83
(2003).
[157] T. Nakamura et al ., Tachyplesin, a class of antimicrobial peptide from the
hemocytes of the horseshoe-crab (tachypleus-tridentatus) - Isolation and che-
mical-structure, Journal of Biological Chemistry , 263, 16709-16713 (1988).
[158] T. Miyata, et al ., Antimicrobial peptides, isolated from horseshoe-crab hemo-
cytes, tachyplesin-Il, and polyphemusin-I and polyphemusin-II - Chemical
structures and biological-activity, Journal of Biochemistry , 106, 663-668
(1989).
[159] M. Morimoto et al ., Inhibitory effect of tachyplesin-I on the proliferation of human-
immunodeficiency-virus in vitro, Chemotherapy , 37, 206-211 (1991).
[160] T. Murakami, M. Niwa, F. Tokunaga, T. Miyata and S. Iwanaga, Direct virus
inactivation of tachyplesin-I and its isopeptides from horseshoe-crab hemocytes,
Chemotherapy , 37, 327-334 (1991).
[161] K. Kawano et al ., Antimicrobial peptide, tachyplesin-I, isolated from hemo-
cytes of the horseshoe-crab (tachypleus-tridentatus) - NMR determination of
the beta-sheet structure, Journal of Biological Chemistry , 265, 15365-15367
(1990).